Rare side effect of tirzepatide therapy

The dual glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide 1 (GLP1) receptor agonist triazepatide has shown promise for improving glycemic control and weight loss. However, it can also have undesirable side effects. Physicians from Abu Dhabi presented a case of hepatotoxicity caused by tirzepatide and emphasized the importance of clinical monitoring during treatment with tirzepatide.